Belonging to the group of monoclonal antibodies, adalimumab’s active ingredients deactivate cytokines including TNF-alpha. It is most commonly used for the treatment of joint diseases such as arthritis.

Molecular size: Large

Controlled Substance: No

Precursor: No

Indications: Immunosuppressant Drugs

Status: Commercial